Skip to content

The Clinical Benefit and Risk of Oral Aspirin for Unruptured Intracranial Aneurysm Combined With Cerebral Ischemia

The Clinical Benefit and Risk of Oral Aspirin for Patients Who Have Unruptured Intracranial Aneurysm Combined With Cerebral Ischemia

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02846259
Acronym
CBROAUNACCI
Enrollment
2135
Registered
2016-07-27
Start date
2016-01-31
Completion date
2019-12-31
Last updated
2016-11-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Ischemia, Intracranial Aneurysm

Keywords

intracranial aneurysm, cerebral ischemia, aspirin

Brief summary

The first purpose of this study is to find out the clinical benefit and risk of oral aspirin for unruptured intracranial aneurysm (small than 7mm) combined with cerebral ischemia in patients in the real world. The second purpose of this study is to get the prediction model of aneurysm's rupture in patients who has unruptured intracranial aneurysm (small than 7mm) combined with cerebral ischemia , and find out who is suitable for oral aspirin.

Detailed description

The investigators try to collect the information of the patients have unruptured intracranial aneurysm combined with cerebral ischemia when oral aspirin.The characteristics of this study are large sample, multi center and prospective.In the real world, more and more patients are checked out unruptured intracranial aneurysm combined with cerebral ischemia.The investigators can collect the information such as how they use aspirin (dose, frequency, duration of treatment), demographic information, past history, daily life habits, morphological characteristics of the aneurysm, how they use other antithrombotic drugs.The investigators will record whether the aneurysm ruptured and have hemorrhage, ischemic stroke, death, changes in the morphology of aneurysm, MRI permeability image index changes. Finally the investigators will get the clinical benefits and risks of using aspirin and build the prediction model of rupture and hemorrhage for aneurysm, find out who is suitable for oral aspirin.

Interventions

None listed

Sponsors

Xuanwu Hospital, Beijing
CollaboratorOTHER
Beijing Chao Yang Hospital
CollaboratorOTHER
Beijing Friendship Hospital
CollaboratorOTHER
The Second Hospital of Hebei Medical University
CollaboratorOTHER
Tianjin Medical University General Hospital
CollaboratorOTHER
Tianjin Huanhu Hospital
CollaboratorOTHER
Beijing Tiantan Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. has the diagnosis of unruptured intracranial aneurysm (using the CTA/DSA,smaller than 7mm) 2. has the history of TIA or any other diseases of cerebral ischemia 3. older than 18 years old 4. sign the informed consent

Exclusion criteria

1. has the history of intracranial aneurysm rupture hemorrhage or has more than one aneurysm untreated 2. has a family history of intracranial aneurysm 3. has AVM,MMD, intracranial tumor, hydrocephalus or intracranial hemorrhage 4. refuse to sign the informed consent 5. allergic to contrast medium

Design outcomes

Primary

MeasureTime frameDescription
Aneurysm rupture hemorrhage2 years during the follow-up periodAneurysm subarachnoid hemorrhage without trauma

Secondary

MeasureTime frameDescription
TIA2 years during the follow-up period
Aneurysm changing2 years during the follow-up periodthe aneurysm becomes bigger, its form changes, becomes two or more
dead2 years during the follow-up period

Countries

China

Contacts

Primary ContactYong Cao, M.D.
caoyong6@hotmail.com010-67096523

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026